AI Article Synopsis

  • * The term malignant eccrine spiroadenoma (MES) was first introduced in 1972, with about 100 reported cases since then.
  • * This text discusses a specific case of MES that developed from a previously benign lesion, including its pathology and treatment approaches.

Article Abstract

Eccrine spiroadenoma arises from adnexal tissue of skin and is usually benign, slow growing and may remain static for decades [1]. Dabska et al. first defined the term malignant eccrine spiroadenoma (MES) in 1972, since then around 100 cases of MES have been found (Alejandra de Andrés Gómez. Malignant eccrine breast spiroadenoma. A case report and literature review [2]). Its very rare kind of tumor can arise either from transformation in benign lesion or can arise de novo. Here we are reporting a case of malignant spiroadenoma arising from transformation of benign lesion, its pathology and treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934780PMC
http://dx.doi.org/10.1007/s12663-021-01561-wDOI Listing

Publication Analysis

Top Keywords

malignant eccrine
12
eccrine spiroadenoma
12
transformation benign
8
benign lesion
8
spiroadenoma
5
malignant
4
spiroadenoma temporal
4
temporal region
4
region reporting
4
reporting rare
4

Similar Publications

Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant neoplasm that originates from the deepest part of the eccrine sweat glands. Characterized by slow growth, PCMC often appears on the head and neck of older patients. Although it rarely metastasizes, its high recurrence rate leads to significant morbidity.

View Article and Find Full Text PDF

Pemetrexed is a chemotherapeutic, antimetabolite agent that has been used in oncology to treat diseases such as metastatic non-small cell lung cancer and unresectable malignant pleural mesothelioma. Pemetrexed use may result in pseudocellulitis, which presents as poorly demarcated patches or plaques with erythema, edema, warmth, and tenderness. These lesions can present unilaterally or bilaterally on the lower extremities.

View Article and Find Full Text PDF

Digital Papillary Adenocarcinoma at the Site of 5 Years of Recurrent Paronychia: Case Report and Literature Review.

Case Rep Oncol Med

December 2024

Hand and Upper Extremity Surgery, Barrington Orthopedic Specialists, Schaumburg, Illinois, USA.

Article Synopsis
  • Digital papillary adenocarcinoma (DPA) is a rare and often misdiagnosed malignant tumor, commonly mistaken for benign conditions, leading to delayed diagnosis and treatment.
  • A 57-year-old man with recurrent finger infections was ultimately diagnosed with DPA after a surgical evaluation and biopsy revealed both infection and the tumor, necessitating surgical removal.
  • Accurate diagnosis is vital due to the tumor's tendency for recurrence and metastasis, particularly to the lungs and lymph nodes, and current treatment primarily involves surgical excision with focus on achieving negative margins.
View Article and Find Full Text PDF

[A case report of eccrine porocarcinoma of the shoulder with cervical lymph node metastasis].

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

December 2024

Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Friendship Hospital, Beijing100029, China.

View Article and Find Full Text PDF

Digital Papillary Adenocarcinoma: A Case Presentation and Literature Review.

J Hand Surg Glob Online

November 2024

Prisma Health Orthopedics, Columbia, SC.

Digital papillary adenocarcinoma is a rare cutaneous tumor of eccrine origin that often presents as a papule or nodule on the dorsal aspect of a finger. It is challenging to diagnose because of its rarity, its benign appearance, and the lack of specific clinical or histological features. Excision is recommended, given the malignant nature and variable recurrence rates with metastases well documented in the literature.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!